A small mechanistic RCT (n=34) found ertugliflozin did not increase proximal tubular natriuresis (the primary outcome) but did reduce fluid volume and blood pressure by week 12. PICO summary and expert commentary.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
A small randomized trial compared perindopril plus indapamide against perindopril plus moxonidine (both with metformin) for left ventricular and renal protection in hypertension with prediabetes. PICO summary and expert commentary.
Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg…
A secondary analysis of the CORDIOPREV trial reports that a lower baseline neutrophil count is associated with type 2 diabetes remission in patients with coronary heart disease following a Mediterranean diet. PICO summary and expert commentary.
A decentralized n-of-1 crossover trial found dapagliflozin lowered the urine albumin-to-creatinine ratio by 15.1% versus placebo over 1-week periods in 20 adults with type 2 diabetes, while demonstrating reliable remote sampling. PICO summary and expert commentary.
A secondary analysis of the EARLIER trial found that diabetes plus CKD predicted worse cardiovascular outcomes in acute heart failure, while eplerenone’s effects appeared consistent across subgroups. PICO summary and expert commentary.
Summary: In adults with chronic kidney disease and overweight or obesity but without diabetes, semaglutide 2.4 mg once weekly for…
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context Diabetic kidney…
A phase 2b randomized trial found that cotadutide reduced urinary albumin-to-creatinine ratio versus placebo in type 2 diabetes with chronic kidney disease, a surrogate signal requiring confirmation. PICO summary and expert commentary.
A pre-specified FLOW subgroup analysis tests whether baseline SGLT2 inhibitor use modifies semaglutide’s kidney and cardiovascular benefit in type 2 diabetes with CKD. PICO summary and expert commentary.